PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
China Resources Pharmaceutical Group Ltd (3320.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINHK0000311099
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic

Highlights

Market CapHK$32.29B
PE Ratio7.79
PEG Ratio4.63
Revenue (TTM)HK$267.33B
Gross Profit (TTM)HK$39.13B
EBITDA (TTM)HK$14.96B
Year RangeHK$4.45 - HK$7.96
Target PriceHK$7.68

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with 3320.HK

China Resources Pharmaceutical Group Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in China Resources Pharmaceutical Group Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%0.00%50.00%100.00%150.00%OctoberNovemberDecember2024FebruaryMarch
-33.45%
149.02%
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

China Resources Pharmaceutical Group Ltd had a return of -0.78% year-to-date (YTD) and -27.78% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-0.78%10.04%
1 month-3.23%3.53%
6 months-4.50%22.79%
1 year-27.78%32.16%
5 years (annualized)-12.21%13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-7.21%11.34%
2023-13.39%-0.76%-6.54%0.41%5.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for China Resources Pharmaceutical Group Ltd (3320.HK) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
3320.HK
China Resources Pharmaceutical Group Ltd
-0.76
^GSPC
S&P 500
2.76

Sharpe Ratio

The current China Resources Pharmaceutical Group Ltd Sharpe ratio is -0.76. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.76
2.74
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

China Resources Pharmaceutical Group Ltd granted a 3.14% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.16 per share.


PeriodTTM2023202220212020201920182017
DividendHK$0.16HK$0.16HK$0.15HK$0.12HK$0.22HK$0.13HK$0.11HK$0.09

Dividend yield

3.14%3.12%2.37%3.38%5.53%1.80%1.08%0.89%

Monthly Dividends

The table displays the monthly dividend distributions for China Resources Pharmaceutical Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024HK$0.00HK$0.00
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.15HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.12HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.22HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.13HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.11HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2017HK$0.09HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%3.1%
China Resources Pharmaceutical Group Ltd has a dividend yield of 3.14%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%24.2%
China Resources Pharmaceutical Group Ltd has a payout ratio of 24.24%, which is quite average when compared to the overall market. This suggests that China Resources Pharmaceutical Group Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-54.01%
0
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the China Resources Pharmaceutical Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the China Resources Pharmaceutical Group Ltd was 72.81%, occurring on Mar 15, 2022. The portfolio has not yet recovered.

The current China Resources Pharmaceutical Group Ltd drawdown is 54.01%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-72.81%Sep 4, 2018870Mar 15, 2022
-19.23%Apr 9, 201860Jul 5, 201839Aug 29, 201899
-10.08%Jul 4, 201729Aug 11, 201766Nov 16, 201795
-8.85%Jan 22, 201815Feb 9, 20185Feb 20, 201820
-8.72%Nov 17, 201714Dec 6, 201719Jan 5, 201833

Volatility

Volatility Chart

The current China Resources Pharmaceutical Group Ltd volatility is 8.02%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%OctoberNovemberDecember2024FebruaryMarch
8.02%
2.82%
3320.HK (China Resources Pharmaceutical Group Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of China Resources Pharmaceutical Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items